Daniel Gruener
Pain Medicine · Philadelphia, PANPI 1871713370
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 30.7% of the total. That places this record below the midpoint for pain medicine clinicians in PA, where the typical reported total is $1,502.
Across 28 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$219
- Alkermes, Inc.$139
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$133
- Otsuka America Pharmaceutical, Inc.$68
- E.r. Squibb & Sons, L.L.C.$52
- Lundbeck LLC$29
- plus $74 from 4 others
Across 883 payments — averaging $3335.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.9M
- Roche TCRC, Inc.$321K
- AbbVie$247K
- Indivior Inc.$120K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$82K
- Alkermes, Inc.$81K
- plus $183K from 15 others
What the payments were for
- Food & beverage$714100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $219 |
| Alkermes, Inc. | 2 | $139 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $133 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 2 | $52 |
| Lundbeck LLC | 1 | $29 |
| Johnson & Johnson | 1 | $20 |
| Cardinal Health 414 LLC | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $14 |
How this compares
$714 in reported general payments places this provider in the 35th percentile of 294 pain medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 14 | $937 |
| Gabapentin | 15 | $270 |
| Zolpidem Tartrate | 14 | $84 |
| Buspirone Hcl | 15 | $68 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $45 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Philadelphia
- Peter PryzbylkowskiPhiladelphia$506K
- Jonathan BeattyPhiladelphia$46K
- John FarrarPhiladelphia$37K
- Uplekh PurewalPhiladelphia$21K
- Megan LinehanPhiladelphia$12K
- Dajie WangPhiladelphia$7K
- Yeshvant NavalgundGreensburg$388K
- Jack SmithWilliamsport$324K
- Sanjay GuptaBala Cynwyd$241K
- Vwaire OrhurhuWilliamsport$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.